New England Journal of Medicine DECEMBER 19, 2019

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.

Bottom Line

Niraparib maintenance therapy significantly extended progression-free survival compared to placebo in patients with newly diagnosed advanced ovarian cancer who had a response to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency status.

Key Findings

1. Among patients with homologous-recombination deficiency (HRD) (n=373), the median progression-free survival was 21.9 months in the niraparib group versus 10.4 months in the placebo group (HR 0.43; 95% CI 0.31-0.59; P<0.001).

2. In the overall population (N=733), median progression-free survival was 13.8 months in the niraparib group versus 8.2 months in the placebo group (HR 0.62; 95% CI 0.50-0.76; P<0.001).

3. At the 24-month prespecified interim analysis, the rate of overall survival was 84% in the niraparib group and 77% in the placebo group (HR 0.70; 95% CI 0.44-1.11).

4. The most common grade 3 or higher adverse events in patients treated with niraparib were anemia (31.0%), thrombocytopenia (28.7%), and neutropenia (12.8%).

Study Design

Design

Randomized Controlled Trial

Double-Blind

Sample

733

Patients

Duration

13.8 mo

Median

Setting

Multicenter, international

Population Patients with newly diagnosed, advanced (stage III or IV) high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer at high risk for relapse, who had achieved a complete or partial response to first-line platinum-based chemotherapy.

Intervention Niraparib administered orally once daily (initially at a 300 mg fixed dose, later amended to an individualized dose of 200 mg or 300 mg based on baseline body weight and platelet count).

Comparator Matched placebo administered orally once daily.

Outcome Progression-free survival (PFS) by blinded independent central review, hierarchically tested first in the homologous-recombination deficiency (HRD) subgroup and then in the overall population.

Study Limitations

• The median follow-up of 13.8 months at the time of the primary analysis was relatively short, leaving the overall survival data immature and preliminary.

• The trial specifically selected for patients at 'high risk' of relapse (e.g., stage III patients with residual macroscopic disease after primary debulking, or stage IV disease), which limits the generalizability of the findings to lower-risk populations such as stage III patients with completely resected disease.

• The initial fixed dosing of 300 mg resulted in significant early hematologic toxicity, necessitating a mid-study protocol amendment to individualize dosing based on body weight and platelet count.

• The trial design compared niraparib to placebo rather than to an active comparator arm containing bevacizumab, leaving the optimal choice of frontline maintenance therapy undefined.

Clinical Significance

The PRIMA trial fundamentally transformed the standard of care for advanced ovarian cancer by demonstrating that frontline maintenance therapy with niraparib confers a substantial progression-free survival benefit to all patients responding to platinum-based chemotherapy. Most notably, the benefit was observed independently of BRCA mutation or HRD biomarker status. This led to the FDA approval of niraparib as a biomarker-agnostic first-line maintenance option, allowing a much broader population of patients—including those who are homologous recombination proficient (HRP)—to benefit from early PARP inhibition.

Historical Context

Prior to the PRIMA trial, the landmark SOLO-1 trial had established the PARP inhibitor olaparib as the standard of care for frontline maintenance in advanced ovarian cancer, but its use was strictly restricted to patients harboring BRCA1/2 mutations. Meanwhile, PARP inhibitors were broadly approved for an all-comer population only in the recurrent, platinum-sensitive setting (e.g., through the NOVA and ARIEL3 trials). PRIMA was the first prospective Phase 3 trial to successfully evaluate a PARP inhibitor as frontline maintenance in an all-comer advanced ovarian cancer population, breaking the biomarker barrier and addressing a major unmet clinical need for patients without actionable mutations.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Niraparib is a PARP inhibitor. Explain the concept of 'synthetic lethality' in the context of PARP inhibition and BRCA mutations. How did the PRIMA trial's finding that niraparib demonstrates efficacy even in HRD-negative patients expand our clinical understanding of PARP inhibitor mechanisms?

Key Response

Synthetic lethality occurs when a defect in one gene (e.g., BRCA) is viable, but simultaneous loss of another (e.g., PARP inhibition) causes cell death due to an inability to repair DNA double-strand breaks. The PRIMA trial's success in HRD-negative tumors indicates that PARP inhibitors exert cytotoxicity through additional mechanisms beyond classic synthetic lethality, such as PARP trapping on DNA, which obstructs replication forks regardless of HRD status.

Resident

The PRIMA trial utilized an 'individualized starting dose' for niraparib rather than a fixed dose for all patients. What specific baseline patient characteristics dictated this dosing change, and what severe toxicity was this strategy specifically designed to mitigate?

Key Response

Niraparib dosing was adjusted based on baseline body weight (less than 77 kg) and/or baseline platelet count (less than 150,000 per microliter) to a lower starting dose of 200 mg daily instead of 300 mg. This was implemented mid-trial to mitigate the high rates of grade 3 or 4 thrombocytopenia seen with the fixed dose, successfully improving the safety profile without compromising oncologic efficacy.

Fellow

While the PRIMA trial demonstrated a statistically significant PFS benefit in the overall population, how does the magnitude of benefit (Hazard Ratio) differ among the BRCA-mutated, HRD-positive/BRCA-wildtype, and HR-proficient subgroups, and how does this influence shared decision-making for a newly diagnosed HR-proficient patient?

Key Response

The Hazard Ratio for PFS was much stronger in the BRCA-mutated (HR approx 0.40) and HRD-positive/BRCA-wildtype (HR approx 0.50) groups compared to the HR-proficient group (HR approx 0.68). Fellows must recognize that while statistically significant, the absolute PFS benefit in HR-proficient patients is smaller. This requires careful counseling regarding the financial toxicity, daily side effects, and rare risks like MDS/AML versus a modest delay in progression.

Attending

The PRIMA trial changed the standard of care based on a Progression-Free Survival (PFS) endpoint. As an attending, how do you contextualize the use of continuous, potentially toxic maintenance therapy in an asymptomatic first-line patient when Overall Survival (OS) data may not show a significant benefit, especially considering the risk of secondary malignancies?

Key Response

Attendings must balance the oncologic goal of delaying recurrence with the reality of chronic low-grade toxicities and rare but fatal risks like MDS/AML. If OS is not significantly improved, maintenance therapy may simply change the timing of toxicities without extending life. This highlights the critical importance of patient-centered values and quality-of-life considerations when offering first-line maintenance, particularly in HR-proficient populations.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The PRIMA trial utilized a hierarchical testing strategy, first assessing the primary endpoint in the HRD-positive population before stepping down to the overall population. What are the statistical advantages of this design in a targeted therapy trial, and what are its limitations when attempting to definitively establish efficacy in the biomarker-negative (HR-proficient) subgroup?

Key Response

Hierarchical testing preserves the family-wise alpha (Type I error rate) across multiple populations, maximizing the statistical power to declare a positive trial in the most sensitive subgroup (HRD-positive). However, the limitation is that the trial was not powered to test the HR-proficient group independently. The overall population's success was heavily driven by the massive benefit in the HRD-positive subset, making the true independent efficacy in the HR-proficient group harder to definitively isolate.

Journal Editor

Approximately one-third of the way through enrollment, the PRIMA protocol was amended to incorporate an individualized starting dose. As an editor, how does a mid-trial protocol amendment of this magnitude threaten the internal validity of the trial, and what specific supplementary analyses would you demand to ensure the robustness of the final results?

Key Response

Mid-trial dosing changes threaten internal validity by creating heterogeneity in the intervention arm, potentially confounding efficacy and safety signals. An editor would demand a robust, pre-specified supplementary analysis comparing efficacy (PFS) and toxicity between the fixed-dose and individualized-dose cohorts to prove the lower dose did not compromise the treatment effect and to accurately define the toxicity profile for clinical practice.

Guideline Committee

Based on the PRIMA trial, how should clinical guidelines stratify recommendations for first-line maintenance therapy in advanced ovarian cancer compared to regimens established by SOLO-1 and PAOLA-1, specifically regarding the necessity of biomarker testing prior to initiation?

Key Response

PRIMA supports a Category 1 recommendation for niraparib maintenance for all platinum-responsive patients, removing the absolute prerequisite for BRCA or HRD testing to initiate therapy (unlike SOLO-1 for BRCAm or PAOLA-1 for HRD-positive). However, NCCN and ASCO guidelines still strongly recommend upfront biomarker testing because it informs the expected magnitude of benefit and helps clinicians choose the most appropriate agent or combination, ensuring personalized, value-based care.

Clinical Landscape

Noteworthy Related Trials

2016

ENGOT-OV16/NOVA Trial

n = 553 · NEJM

Tested

Niraparib maintenance

Population

Platinum-sensitive recurrent ovarian cancer

Comparator

Placebo

Endpoint

Progression-free survival (PFS)

Key result: Niraparib significantly prolonged progression-free survival compared to placebo in patients with recurrent ovarian cancer, regardless of germline BRCA mutation status.

2018

SOLO-1 Trial

n = 391 · NEJM

Tested

Olaparib maintenance

Population

Newly diagnosed advanced ovarian cancer with BRCA mutation

Comparator

Placebo

Endpoint

Progression-free survival (PFS)

Key result: Olaparib significantly improved progression-free survival compared to placebo in women with BRCA-mutated advanced ovarian cancer.

2019

PAOLA-1 Trial

n = 806 · NEJM

Tested

Olaparib plus bevacizumab maintenance

Population

Newly diagnosed advanced ovarian cancer responding to first-line chemotherapy

Comparator

Placebo plus bevacizumab

Endpoint

Progression-free survival (PFS)

Key result: The addition of olaparib to bevacizumab maintenance significantly improved progression-free survival, particularly in patients with HRD-positive tumors.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis